RealiseD Webinars: Driving Innovation in Rare Disease Clinical Trials
The RealiseD project will host a series of four-part webinars that will focus on key topics aimed at reshaping the landscape of clinical research for rare and ultra-rare diseases.
From 13 January to 10 February, the RealiseD project will host a series of four-part webinars that will focus on key topics aimed at reshaping the landscape of clinical research for rare and ultra-rare diseases.
The series will tackle some of the most critical challenges in the field, including the complexity of trial methodologies and the urgent need for patient-centered approaches.
What to expect
· Key principles for designing and running trials in ultra-rare conditions
· Insights on navigating regulatory and HTA pathways
· Approaches to patient-centred and cutting-edge trial methodologies
· Guidance from leading experts in the rare disease community
Register now and join the discussion with leading specialists!
ABOUT THE PROJECT
The initiative, under the leadership of Sigmund Freud Private University and AstraZeneca, aims to optimise and accelerate the development of treatments for over 30 million people living with rare diseases across Europe, the majority of whom suffer from ultra-rare conditions with no available treatment options.
The RealiseD consortium will focus on addressing key challenges in clinical trials, including limited patient populations, high symptom variability, and fragmented regulatory frameworks.
The project also aims to foster collaboration with European Reference Networks (ERNs) particularly (e.g., ERN ERKNet, ERN Epicare, ERN Bond, MetabERN, ERN-EuroBloodNet and ERN-EYE). They will help establish a network of top-notch clinical trial sites across Europe and streamline patient recruitment, particularly for cutting-edge therapies like Advanced Therapy Medicinal Products (ATMPs).